Roth Capital raised the firm’s price target on iRadimed (IRMD) to $120 from $98 and keeps a Buy rating on the shares following “strong” Q4 results. The firm cited higher forward estimates and continued confidence in the business for the price target bump. Roth added that it expects iRadimed will build 100-130 new 3870 pumps in April for shipment by May and incrementally more thereafter.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRMD: